Failure to thrive: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data by Ross, Elizabeth et al.
eCommons@AKU 
Department of Paediatrics and Child Health Division of Woman and Child Health 
12-4-2017 
Failure to thrive: Case definition & guidelines for data collection, 
analysis, and presentation of maternal immunisation safety data 
Elizabeth Ross 
Monash Children's Hospital, Melbourne, Australia 
Flor M. Munoz 
Baylor College of Medicine, Houston, TX, USA. 
Bassey Edem 
University of Siena, Italy 
Cassandra Nan 
GlaxoSmithKline, Stevenage, UK. 
Fyezah Jehan 
Aga Khan University, fyezah.jehan@aku.edu 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr 
 Part of the Pediatrics Commons 
Recommended Citation 
Ross, E., Munoz, F. M., Edem, B., Nan, C., Jehan, F., Quinn, J., Moore, T. M., Sesay, S., Spiegel, H., Fortuna, L. 
(2017). Failure to thrive: Case definition & guidelines for data collection, analysis, and presentation of 
maternal immunisation safety data. Vaccine, 35(48 Pt A), 6483-6491. 
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/394 
Authors 
Elizabeth Ross, Flor M. Munoz, Bassey Edem, Cassandra Nan, Fyezah Jehan, Julie Quinn, Tamala Mallett 
Moore, Sanie Sesay, Hans Spiegel, and Librada Fortuna 
This response or comment is available at eCommons@AKU: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr/394 
Commentary
Failure to thrive: Case definition & guidelines for data collection,
analysis, and presentation of maternal immunisation safety data
Elizabeth Ross a, Flor M. Munoz b, Bassey Edem c, Cassandra Nan d, Fyezah Jehan e, Julie Quinn f,
Tamala Mallett Moore g, Sanie Sesay h, Hans Spiegel i, Librada Fortuna j, Sonali Kochhar k,m,1, Jim Buttery l,⇑,
for The Brighton Collaboration Failure to Thrive Working Group 2
aMonash University, Department of Paediatrics, Monash Children’s Hospital, Melbourne, Australia
bBaylor College of Medicine, Departments of Paediatrics, Molecular Virology and Microbiology, Houston, TX, USA
cVaccinology and Pharmaceutical Clinical Development, University of Siena, Italy
dGlaxoSmithKline, Stevenage, UK
eAga Khan University, Department of Paediatrics and Child Health, Pakistan
fMonash Children’s Hospital, Infection and Immunity, Department of Paediatrics, The Ritchie Centre, Hudson Institute, Monash University, SAEFVIC,
Murdoch Children’s Research Institute, Victoria, Australia
g Sanofi Pasteur Inc., Swiftwater, PA, USA
h Sanofi Pasteur, France
iKelly Government Solutions (KGS), Rockville, MD, USA
jBioNet-Asia, Thailand
kGlobal Healthcare Consulting, India
lMonash University, Department of Paediatrics, Infection and Immunity, Monash Children’s Hospital, Monash Health; SAEFVIC, Murdoch Children’s Research Institute,
Melbourne, Australia
m Erasmus University Medical Center, Rotterdam, The Netherlands
a r t i c l e i n f o
Article history:
Received 6 December 2016








a b s t r a c t
 2017 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).
1. Preamble
1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for failure to thrive as an adverse
event following maternal immunisation
Failure to thrive (FTT) is a descriptive term for insufficient
growth, usually identified in infancy. Definitions of FTT typically
incorporate both clinical characteristics of insufficient growth
and specific anthropometric criteria which define it.
Literature related to defining FTT can be broadly categorized in
terms of anthropometric indices, aetiological causes, and a variety
of variably interchangeable descriptors used to describe FTT or rel-
evant clinical terms. There is no agreed definition and utilisation
studies of existing definitions have largely been limited by small
sample sizes, apart from two European infant cohorts. These
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studies agreed that all current means of diagnosing FTT either over
or under diagnose the condition and a more accurate diagnostic
tool could be beneficial [1,2]. This paper focuses upon FTT in the
first year of life, to assist the investigation of any potential con-
cerns regarding reduced growth in infancy following antenatal
maternal immunisation.
Key anthropometric terms include child growth, growth assess-
ment, growth chart monitoring, growth monitoring, and nutri-
tional status. Aetiological literature attempting to define FTT
includes the areas of malnutrition and feeding disorders. Relevant
clinical descriptors include child health, failure to thrive, growth
interruption, growth retardation, weight/growth faltering, malnu-
trition, wasting, stunting and feeding disorder.
FTT is used as a diagnosis, or a description of a weight gain
pattern.
Anthropometric indices have been used universally for defining
FTT, yet there is heterogeneity regarding the specific indices, for
example weight for age versus weight for height/length. Under-
nutrition or inadequate nutrition is thought to be the underlying
factor with the consequence of significant interruption to the
expected rate of growth, and is strongly linked to malnutrition.
In low income countries, malnutrition manifesting as failure to
thrive is more common [2–7].
Normal growth is described in reference to what is regarded as
abnormal growth, falling below a pre-determined centile, usually
the 3rd. This gives no direct estimate of growth, only of attained
weight and clinically children may deviate from their earlier cen-
tile position. The growth curve of a normally growing child will
represent gradual and incremental increases in weight from birth
and is based on regular weight recordings [8,9].
Among infants, determining FTT presents its own set of chal-
lenges. For example, in infants and young children with genetic
short stature, prematurity, or intrauterine growth restriction who
have an acceptable weight-for-length and normal growth velocity
the term FTT is not used [10,11]. Additionally, the well-recognized
phenomenon of some healthy infants born above expected weight
to experience an initial fall below birth centiles over the first 6–
12 months, before following their ‘‘correct” centile, also known as
‘regression to the mean’, further complicates the specificity of
FTT definitions based upon growth trajectory [12,13]. This phe-
nomenon has also been termed ‘‘catch down” growth [14].
Finally, there is little consensus as to what constitutes a normal
rate of weight gain.
Evolution of FTT as a description:
The term FTT was not used until the 1930s and has evolved to
describe under-nutrition resulting in a growth deviation or falter-
ing regardless of the underlying cause. It is predominately based on
anthropometrical parameters but no consensus on the choice of
anthropometric indices has been agreed upon nor the criteria for
abnormality. The literature acknowledges the lack of standardisa-
tion and recognizes that no one definition will be applicable or
appropriate for all purposes but also acknowledges a need for
clearly stated anthropometrical indices and cutoff points for the
sake of scientific comparisons [3,15,16].
Prevalence of FTT depends on risks within populations. In low
income settings, infectious diseases, poverty and inadequate nutri-
tion are the primary risks.
In high income countries, the primary risks are preterm birth,
and family dysfunction but in the majority of children with FTT
an underlying medical condition is not found.
The described prevalence depends mainly on the definition
being used and the demographics of the population being studied,
with higher rates occurring in economically disadvantaged rural
and urban areas. The UNICEF 2013 report states that globally,
about one in four children under 5 years old are stunted from
under-nutrition. An estimated 80 per cent of the world’s 165 mil-
lion stunted children live in just 14 countries. Globally 26 per cent
of children under 5 are stunted, however in sub-Saharan Africa and
South Asia this number reaches nearer to 40 per cent, while in the
most affected countries (Timor-Leste, Burundi, Niger and Madagas-
car) over 50 per cent of children under 5 are considered stunted
[17] Studies show that in some developing countries growth falter-
ing often starts soon after birth. In a study in Guatemala, depend-
ing on the reference standard used, 19 and 34% of the weight
deficit observed in growth-restricted 3 year old children was
attributed to failure to thrive during the first 3 months of life
[18]. Children who are malnourished at 3–5 years of age often pre-
sented with anthropometric deficits at the end of their first year of
life [19].
The community prevalence of FTT in high income countries is
reported to be 1–10% under 2 years of age, with the United States
seeing 5–10% of children presenting in primary care settings and
3–5% of children in hospital settings [7,20–22]. In all settings there
are a myriad of causes.
Conventional classification of FTT:
 Organic FTT-occurs in less than 5% of FTT cases-due to acute or
chronic disorders that interfere with nutritional uptake such as
cleft palate, malabsorption due to cystic fibrosis, and short gut
syndrome.
 Non organic FTT-is attributed to inadequate intake with no
apparent growth-inhibiting organic disorder. This can be due
to environmental influences, stimulus deprivation-poverty,
feeding techniques, or psychological reasons.
 Mixed FTT-organic and non-organic causes can overlap [22–24]
Existing case definitions for failure to thrive:
The difficulty in achieving a robust definition of FTT is due to
both the limited number of available parameters to measure, and
defining an abnormal change in these parameters given so much
variability in normal patterns of growth in the first 12 months of
life. While many infants can be expected to track along their
defined growth centile, some healthy infants will not. Existing def-
initions of FTT do not easily distinguish between healthy infants
with varied growth patterns and those who truly have FTT. A
2007 review of seven FTT criteria applied to a Danish birth cohort
of 6090 infants found low specificity, with 27% of infants meeting
one or more criteria, with most single criteria identifying less than
half of the infants with known significant under-nutrition [2].
Healthy infants who may satisfy existing definitions of FTT include
genetic short stature, preterm infants (if uncorrected for gestation),
constitutional growth delay, and larger infants ‘‘regressing to the
mean” [14].
FTT is consistently evaluated on anthropometrical indicators of
weight and length/height. In practice, weight gain is the predomi-
nant indicator of choice. Weight is the first value affected in a child
with FTT, followed by length if the FTT persists. A delay in growth
of head circumference is only affected in severe cases, demonstrat-
ing the need to follow growth parameters over time. Assessment of
length is desirable to better track stunting and to assess aetiology
of low weight [7,25,26].
Using weight as the indicator FTT is described as a reduction in
the expected rate of growth along an infant’s previously defined
curve [27]. One common way of diagnosing FTT using weight is as
a weight less than the third or fifth percentile for age on more than
one occasion. Thismay falsely identify those infants naturally small,
such as constitutional low weight while excluding larger infants
with inadequate growth and true FTT whose weights do not fall
below the lower centiles. An alternative definition of FTT is weight
measurements that fall 2 major percentile lines between 2 or more
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time points. This definitionmay falsely include healthy infants who
‘‘regress toward themean”while excluding infants with lowweight
where falling 2 major centiles is not possible [3,4,8,21].
The measurement indices of weight and height/length in an
equation to calculate a Body Mass Index (BMI) can also be used
to identify children that are underweight. It is useful as a screening
tool for wasting and thinness, but is not recommended for children
younger than 2 years as there has been little research on what BMI
calculated from length means in infancy [28,29].
In low andmiddle income countries (LMIC) the use of bodymea-
surements are used to assess nutritional status. Body measure-
ments in use include: weight; length in children under 24 months
or under 87 cm in height; and mid-upper arm circumference
(MUAC). Nutritional indices are calculated by comparing an individ-
ual’s measurements with that of a reference population. The nutri-
tional indices commonly calculated for young children are:
 Weight for length: a measure of wasting or acute malnutrition.
 Height for age: a measure of stunting or chronic malnutrition.
 Weight for age: a measure of underweight or wasting and
stunting combined.
However, as discussed earlier, faltering length presents later
than changes in weight alone.
MUAC is also an important measure of wasting or acute malnu-
trition but is not an index by itself. It is used for rapid assessments
as it identifies wasting and is a globally endorsed selection criteria
for entry into selective feeding programs as it is a rapid and effec-
tive predictor of risk in children aged 6–59 months [30].
WHO and UNICEF recommend to define severe acute malnutri-
tion (SAM) in infants using of weight for height indicators with the
cutoff of below 3 standard deviations and a MUAC cut-off point of
115 mm to define SAM with MUAC [5,31]. In infants aged from
birth to 6 months, minimal data exists as to a reliable MUAC for
diagnosing SAM. One small study from Indian suggests a lower
range of 110 mm for infants 1–6 months of age [32].
The International Classification of Diseases (ICD-10) defines
Failure to thrive as the lack of expected normal physiological
development and defines Malnutrition as ‘‘The degree of malnutri-
tion is usually measured in terms of weight, expressed in standard
deviations from the mean of the relevant reference population.
When one or more previous measurements are available, lack of
weight gain in children, or evidence of weight loss in children or
adults, is usually indicative of malnutrition. When only one mea-
surement is available, the diagnosis is based on probabilities and
is not definitive without other clinical or laboratory tests. In the
exceptional circumstances that no measurement of weight is avail-
able, reliance should be placed on clinical evidence” [32].
As anthropometric indicators remain the measures of choice in
low and high income communities, the working group elected to
use weight-for-age as the primary measure. Weight is widely
applicable with staff being skilled and most comfortable in mea-
suring weight as a primary tool in all settings throughout LMIC
and HIC. As previously discussed, length/height is not well vali-
dated in the target population of infants up to 12 months of age.
Weight for age below the third or fifth centile does not adequately
cover infants with FTT who do not fall to such low weights. As such
weight for age with a fall through two major centiles is used as the
primary diagnostic measure. Infants with FTT who score falsely
negative in the upper levels of certainty may still be diagnosed
with FTT based on a weight for length ratio below the third centile.
Accurate, reliable measurements are integral to growth moni-
toring and the clinical judgments of a child’s growth pattern. The
choice of measuring equipment, implementation and interpreta-
tion of measurements, and the common practices embedded in
many cultures present significant challenges to establishing robust
definitions for FTT [33]. Correct measurement, plotting, and inter-
pretation are essential for identifying growth problems. The mea-
surements of weight, length/height and MUAC, in combination
with the infant’s age and sex, gauge growth or failure to grow.
Age is generally recorded in months. This information can be
derived from a known date of birth (such as from birth registration
or health cards) or can be based on an estimate derived from a cal-
endar of local events or mother’s recall [30,34].
Various types of scales are used for weighing young children.
The most precise form of measurement is using an electronic scale,
widely used in HIC. These also allow the child to be measured in a
care givers arms if necessary. In LMIC, the most commonly used in
community settings is the hanging spring balance, which can
weigh children up to 25 kg. Beam balance scales are also widely
used in clinical settings, and are considered more precise than
hanging spring balances.
Length is measured on a length board, infantometer, for a child
less than 2 years old (less than 87 cm) in the recumbent position
(crown-heel) measuring to the nearest 0.1 cm.
Growth charts are used to record a child’s measurement against
children of the same age and sex, a reference standard. Centile
charts are used and normal growth constitutes the tracking along
the birth centile [5]. There are no percentile lines between 0 and
2 weeks of age as it is difficult to assess the normal postnatal weight
loss. Signs indicative of poor weight gain for the neonate can
include: a loss of more than 10% of birth weight in the first week,
an average weight gain of less than 105 g per week or unexplained
weight loss in infants 2 weeks to 3 months of age and poor weight
gain compared to growth in length and head circumference [35].
In conjunction with growth charts, examination of clinical signs
also determines a child who is failing to thrive. Physical examina-
tion can be used as an indicator for FTT where there are no mea-
surements or are used in combination. Clinical signs include a
loss of subcutaneous fat stores, poor muscle mass, loose skin folds,
prominent ribs, thin limbs, sparse hair, rashes, pallor, lethargy, can
indicate the level of FTT [23,25,36–38].
Current assessment worldwide of FTT:
The 2006 World Health Organisation (WHO) international
growth charts for children <24 months are consistently recom-
mended for use in the assessment of potential FTT. The WHO
growth charts screen for possible abnormal or unhealthy growth.
WHO recommends cutoff values of ±2 standard deviations, which
correspond to the 2.3rd and 97.7th percentiles (modified to 2nd
and 98th percentile) to define abnormal growth [39].
The charts illustrate the way healthy children should grow and
are considered to be the gold standard for assessing the growth of
young children [37,40]. The growth of preterm infants (less than
37 weeks) can be monitored using the WHO Child Growth Stan-
dards with measurements plotted using corrected postnatal age
for prematurity (ie, postnatal age in weeks  [40 weeks  gesta-
tional age in weeks]) until 24 or 36 months of age. Breastfed
infants born with low birth weight will be expected to track along
the lower percentiles of the WHO charts because exclusive breast-
feeding does not change the fact that they were small for age at
birth [41].
The desired outcome with the use of the WHO growth charts is
to promote consistent practices in monitoring growth and assess-
ing atypical patterns [40]
Indicators used to determine growth are: length/height-for-age;
weight-for-age; weight-for-length/height.
Limitations of growth charts:
The basis of growthmonitoring ismeasuring accurately, plotting
on a growth chart and interpreting the growth curve. Growth data
can therefore be inaccurate due to a number of factors including;
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 deficiencies in the technical aspects of weighing and charting,
and interpreting growth charts
 inadequate training of health workers
 situations where the child’s age cannot be accurately
determined
 a child may also be underweight either because of short length/
height (stunting) or thinness or both
 loss of follow-up, usually due to failure to attend clinics
 operational issues and maintenance of measurement equip-
ment to ensure accuracy of measurements [42,43]
Failure to thrive and immunisation: What is known in
literature?
A search for terms describing FTT as adverse event following
vaccination identified only articles suggesting immunisation visits
as an opportunity for diagnosis of FTT, or under-immunisation
being associated with increased risk of FTT [44,45]. No articles
were identified describing FTT as an adverse event following
immunisation. A search of the US Vaccine Adverse Event Reporting
System (VAERS) database (performed July 2016) described 47
reports where FTT was included in adverse event descriptions.
There is no uniformly accepted definition of FTT in vaccine
pharmacovigilance. This represents a missed opportunity, as data
comparability is crucial to enable both systematic analysis of clin-
ical trial safety as well as meaningful surveillance and investiga-
tion of adverse events reported in existing programs. The
increasing implementation of vaccination programs in pregnancy,
and breadth of antenatal vaccine research in diverse healthcare
settings where FTT is seen, makes the development of a definition
able to be used in all of these settings urgent. The proposed case
definition will refer only to infants up to 12 months of age.
1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for failure to thrive as an
adverse events following maternal immunisation
Following the process described in the overview paper [20] as
well as on the Brighton Collaboration Website http://www.
brightoncollaboration.org/internet/en/index/process.html, the
Brighton Collaboration Failure to Thrive Working Group was formed
in 2016 and included members of clinical, academic, public health
and industry background. The composition of the working and ref-
erence group as well as results of the web-based survey completed
by the reference group with subsequent discussions in the working
group can be viewed at: http://www.brightoncollaboration.org/in-
ternet/en/index/working_groups.html.
To guide the decision-making for the case definition and guide-
lines, a literature search was performed using Medline, Embase
and the Cochrane Libraries, including the terms infant, failure to
thrive, growth retardation, growth failure, growth monitoring,
growth faltering, under-nutrition and anthropometric. The search
resulted in the identification of 1296 references, limited to English
language. All abstracts were screened for possible reports of FTT
following immunisation. One hundred and fifty articles with
potentially relevant material were reviewed in more detail, in
order to identify studies using case definitions or, in their absence,
providing clinical descriptions of the case material. This review
resulted in a detailed summary of 70 articles, including informa-
tion on the study type, the vaccine, the diagnostic criteria or case
definition put forth, the time interval since time of immunisation,
and any other symptoms. Multiple general medical, paediatric and
infectious disease text books were also searched.
Most publications identified were case series. The terminology
was very inconsistent. Very few used case definitions at all and
no two studies used the same definition. An inventory comprising
nine relevant case definitions of FTT was made available to
working group members.
1.3. Rationale for selected decisions about the case definition of failure
to thrive as an adverse event following maternal immunisation
The term failure to thrive
– FTT is the most commonly used term to describe inadequate
growth in infancy, however multiple terms exist, with aetiolog-
ical descriptions often replacing FTT. The most common of these
are malnutrition and under-nutrition, the most common causes
of FTT worldwide.
– As with all Brighton Collaboration case definitions, the FTT def-
inition presented includes differing levels. These do not reflect
clinical severity, rather how confident FTT can be diagnosed
from the information available about the individual case being
assessed (see below). Given the wide range of settings, equip-
ment used, measurements taken and number of assessment
time points, this is especially important for FTT.
Related term(s) of Failure to Thrive
Malnutrition/under-nutrition represents the most common
cause of FTT globally. Differential diagnoses of FTT that may pre-
sent in infancy include: genetic short stature; constitutional
growth delay; ‘‘regression to the mean” also known as ‘‘catch down
growth”; and preterm infants whose gestational age is not cor-
rected appropriately [14].
Formulating a case definition that reflects diagnostic certainty:
Weighing specificity versus sensitivity
It needs to be re-emphasised that the grading of definition
levels is entirely about diagnostic certainty, not clinical severity
of an event. Thus, a clinically very severe event may appropriately
be classified as Level 2 or 3 rather than Level 1 if it could reason-
ably be of non-FTT aetiology. Detailed information about the sever-
ity of the event should additionally always be recorded, as
specified by the data collection guidelines.
The number of symptoms and/or signs that will be documented
for each case may vary considerably. The case definition has been
formulated such that the Level 1 definition is highly specific for
the condition. As maximum specificity normally implies a loss of
sensitivity, two additional diagnostic levels have been included in
the definition, offering a stepwise increase of sensitivity from Level
1 down to Level 3, while retaining an acceptable level of specificity
at all levels. In this way it is hoped that all possible cases of FTT can
be captured.
Rationale for individual criteria or decisions made related to the
case definition
It is widely agreed that a definition of FTT should be based on
anthropometric data, although choice ofwhich variables to use con-
tinues to be debated. Pathology, radiology and laboratory findings
may have a role in determining the cause of failure to thrive and
its differential diagnoses, but do not formpart of this case definition.
Timing post maternal immunisation
Specific time frames for onset of symptoms following maternal
immunisation are not included for the following main reasons:
The limited data available on possible FTT post maternal immu-
nisation means a timeframe cannot be determined. For research
purposes, the working group elected to focus the case definition
on infants. That is, less than 12 month of age.
We postulate that a definition designed to be a suitable tool for
testing causal relationships requires ascertainment of the outcome
(e.g. FTT) independent from the exposure (e.g. immunisations).
Therefore, to avoid selection bias, a restrictive time interval from
immunisation to onset of FTT should not be an integral part of such
a definition. Instead,where feasible, details of this interval should be
assessed and reported as described in the data collection guidelines.
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Further, FTT often occurs outside the controlled setting of a clin-
ical trial or hospital. In some settings, it may be impossible to
obtain a clear timeline of the event, particularly in less developed
or rural settings. In order to avoid selecting against such cases,
the Brighton Collaboration case definition avoids setting arbitrary
time frames.
Differentiation from other (similar/associated) disorders
– Genetic short stature: infants born to small parents are typically
small from birth and grow along their low percentile for both
height and weight, sometimes dipping below their weight cen-
tile briefly. Parental height and weight information helps inform
this diagnosis.
– Constitutional delay in growth: these infants may present with
delayed length and occasionally weight compared with their
same age peers. A family history of constitutional delay in par-
ents or siblings may point to the diagnosis. Delayed bone age
assessment is helpful above 12 months but is less reliable in
infants.
– Preterm infants, if their growth is uncorrected on growth charts
for gestation, will grow below the normal growth curve. Gesta-
tion of the baby in weeks should be recorded, and corrected
before plotting on growth charts.
– Regression to the mean or ‘‘catch down growth” may occur in
large babies (for example macrosomic babies born to mothers
with gestational diabetes) may involve periods of lower growth
that crosses centiles, followed by steady growth along a lower
centile. Maternal history of diabetes and parental height and
weight information may help identify this condition. However,
this is a diagnosis made in retrospect typically, after the estab-
lishment of growth along the infant’s ‘‘true” centile.
FTT case definitions are limited by the difficulty in differentiat-
ing pathological FTT from the above conditions, especially in
infancy when only limited time is available to observe growth pat-
terns. Ideally, infants should be monitored regularly throughout
their first 12 months to establish a true growth pattern and assess
whether it is inadequate. Diagnosis of the above differentials
should be based on history, examination and further investigations
to exclude pathological causes of faltering growth.
Finally, pathological FTT results from a variety of causes which
are not dealt with in these guidelines. These can be broadly
grouped into one or more aetiological categories of poor oral nutri-
ent intake, poor nutrient absorption, or increased caloric consump-
tion (e.g. due to underlying disease). Similarly assessment of
vaccine causality in FTT is not dealt with in this guideline, however
should be managed in accordance with recent WHO vaccine
adverse event guideline [46].
1.4. Guidelines for data collection, analysis and presentation
Asmentioned in the overview paper, the case definition is accom-
panied by guidelines which are structured according to the steps of
conducting a clinical trial, i.e. data collection, analysis and presenta-
tion. Neither case definition nor guidelines are intended to guide or
establish criteria for management of ill infants, children, or adults.
Both were developed to improve data comparability.
1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.
Validation of this case definition in developed and developing set-
tings should help inform further revision of this case definition.
2. Case definition of failure to thrive2
For all levels of diagnostic certainty
FTT can be broadly defined as a faltering of growth from a pre-
viously established pattern of growth. It is universally established
that a diagnosis of failure to thrive should be based on anthropo-
metric data. However no consensus exits as to which measure-
ments achieve the highest specificity and sensitivity. Weight is
generally regarded is the indicator of choice, particularly a change
in growth velocity, and as such has been selected as the standard
for this case definition with a weight for age deceleration as the
primary indicator of failure to thrive.
Level 1 of diagnostic certainty
– Infant age3 determined by a documented birth date
AND
– Weights obtained using an electronic scale
AND
– At least 2 weights, measured at least 4 weeks apart
AND
– Weight for age deceleration4 through at least 2 centile spaces on
growth chart5
Level 2 of diagnostic certainty
Level 2a:
– Infant age determined by a documented birth date
AND
– Weights obtained using a beam balance scale
AND
– At least 2 weights, measured at least 4 weeks apart
AND
– Weight for age deceleration through at least 2 centile spaces on
growth chart
OR
– Infants with an undocumented birth date, where age is deter-
mined based on Mothers recall to nearest month
AND
– Weights obtained using electronic scale
AND
– At least 2 weights, measured at least 4 weeks apart
AND
– Weight for age deceleration through at least 2 centile spaces on
growth chart
Level 2b:
– Infant age determined by a documented birth date
2 The case definition should be applied when there is no clear alternative diagnosis
for the reported event to account for the combination of symptoms.
3 Age: This case definition is limited to infants up to 12 months of age.
4 Weight and Length: Weight should be documented on the appropriate growth
chart at the time of assessment. A fall through 2 centile spaces may be demonstrated at
any point in the first 12 months of life, using any twoweights as long as they are taken
at least 4 weeks apart. Details of use of the weight balances allowable under this case
definition and use of the Infantometer for length assessment are in Appendix A.
5 Growth charts: For infants born at 37 weeks gestation or above, the WHO growth
charts should be applied. When using weight for age use the growth chart most
accurate for the infants age. The birth to 6 months age range should be used where
data is available for this range only, the birth to 2 years chart should be used where
data is available beyond 6 months of life. When using weight for length, use the chart
for birth to 2 years. For infants born less than 37 completed weeks gestation, the
Intergrowth charts for postnatal growth standards in preterm infant should be used.
All infants should be plotted on their respective growth chart using their corrected
age. Links to relevant growth charts can be found in Appendix A.
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AND
– Weights obtained using a spring balance scale
AND
– At least 2 weights, measured at least 4 weeks apart
AND
– Weight for age deceleration through at least 2 centile spaces on
growth chart
OR
– Weight measured using electronic scale or beam balance scale
AND
– Length taken using Infantometer
AND
– Weight for length less than or equal to the 3rd centile on the
appropriate growth chart
Level 3 of diagnostic certainty
Level 3a:
– Infants with an undocumented birth date, where age is deter-
mined based on Mothers recall to nearest month
AND
– Weight obtain using either beam balance or spring balance
scale
AND
– At least 2 weights, measured as least 4 weeks apart
AND
– Weight for age deceleration through at least 2 centile spaces on
growth chart
Level 3b:
– Infants with no weight available
AND
– Physical examination consistent with FTT6
AND
– MUAC7 indicative of severe wasting
3. Guidelines for data collection, analysis and presentation of
failure to thrive
It was the consensus of the Brighton Collaboration Failure to
Thrive Working Group to recommend the following guidelines to
enable meaningful and standardised collection, analysis, and pre-
sentation of information about Failure to thrive. However, imple-
mentation of all guidelines might not be possible in all settings.
The availability of information may vary depending upon
resources, geographical region, and whether the source of infor-
mation is a prospective clinical trial, a post-marketing surveil-
lance or epidemiological study, or an individual report of Failure
to Thrive. Also, as explained in more detail in the overview paper
in this volume, these guidelines have been developed by this
working group for guidance only, and are not to be considered a
mandatory requirement for data collection, analysis, or
presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on availability following maternal immunisation to
allow for comparability of data, and are recommended as an addi-
tion to data collected for the specific study question and setting.
The guidelines are not intended to guide the primary reporting of
Failure to Thrive to a surveillance system or study monitor. Inves-
tigators developing a data collection tool based on these data col-
lection guidelines also need to refer to the criteria in the case
definition, which are not repeated in these guidelines.
Guidelines numbers below have been developed to address data
elements for the collection of adverse event information as speci-
fied in general drug safety guidelines by the International Confer-
ence on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ref), and the form
for reporting of drug adverse events by the Council for Interna-
tional Organizations of Medical Sciences (ref). These data elements
include an identifiable reporter and patient, one or more prior
immunisations, and a detailed description of the adverse event,
in this case, of Failure to Thrive following maternal immunisation.
The additional guidelines have been developed as guidance for the
collection of additional information to allow for a more compre-
hensive understanding of Failure to Thrive following maternal
immunisation.
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting8 and/or
diagnosing the Failure to Thrive as specified by country-speci-
fic data protection law.
(3) Name and contact information of the investigator responsi-
ble for the subject, as applicable.
(4) Relation to the patient (e.g., immuniser [clinician, nurse],
family member [indicate relationship], other).
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants, as
appropriate, the following information should be recorded:
(5) Case/study participant identifiers (e.g. first name initial fol-
lowed by last name initial) or code (or in accordance with
country-specific data protection laws).
(6) Date of birth, age, and sex.
(7) For infants: Gestational age and birth weight. Parental
height and weight (both parents if known)
3.1.2.2. Clinical and immunisation history. For all cases and/or all
study participants, as appropriate, the following information
should be recorded:
(8) Past medical history, including hospitalisations, underlying
diseases/disorders, pre-immunisation signs and symptoms
including identification of indicators for, or the absence of,
a history of allergy to vaccines, vaccine components or med-
ications; food allergy; allergic rhinitis; eczema; asthma.
Maternal history of underlying diseases/disorders, gesta-
tional diabetes.
6 Physical examination with signs of Failure to Thrive (must include at least 2
findings, with at least one major finding)Major findings: Reduced subcutaneous fat
stores; poor muscle mass; loose skin folds; prominent ribs; thin limbsOther less
specific signs include: sparse hair; rashes; pallor; miserable; lethargy/fatigue.
7 Mid Upper Arm Circumference (MUAC):For infants 0–6 months, a MUAC
of 6 110 mm is indicative of severe wasting.For infants 6–12 months, a MUAC
of 6 115 mm is indicative of severe wasting. Instructions on performing MUAC are in
Appendix A.
8 If the reporting centre is different from the vaccinating centre, appropriate and
timely communication of the adverse event should occur.
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(9) Any medication history (other than treatment for the event
described) prior to, during, and after immunisation includ-
ing prescription and non-prescription medication as well
as medication or treatment with long half-life or long term
effect. (e.g. immunoglobulins, blood transfusion and
immunosuppressants). Maternal medication history during
pregnancy.
(10) Maternal immunisation history (i.e. previous immunisations
and any adverse event following immunisation (AEFI)), in
particular occurrence of Failure to Thrive after a previous
immunisation.
3.1.3. Details of the immunisation
For all cases and/or all study participants, as appropriate, the
following information should be recorded for both infant and
mother (if immunized in pregnancy):
(11) Date and time of immunisation(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL, etc) and number of dose
if part of a series of immunisations against the same
disease).
(13) The anatomical sites (including left or right side) of all
immunisations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically document:
(17) Clinical description of signs and symptoms of Failure to
Thrive, and if there was medical confirmation of the event
(i.e. patient seen by physician).
(18) Date/time of onset9, first observation10 and diagnosis11, end
of episode12 and final outcome.13
(19) Concurrent signs, symptoms, and diseases.
(20) Measurement/testing
 Values and units of routinely measured parameters (e.g.
temperature, blood pressure) – in particular those indi-
cating the severity of the event;
 Method of measurement (e.g. type of thermometer, oral
or other route, duration of measurement, etc.);
 Results of laboratory examinations, surgical and/or
pathological findings and diagnoses if present.
(21) Treatment given for Failure to Thrive, especially specify
what and dosing/duration if applicable.
(22) Outcome12 at last observation.
(23) Objective clinical evidence supporting classification of the
event as ‘‘serious”.14
(24) Exposures other than the immunisation before and after
immunisation (e.g. food, environmental) considered poten-
tially relevant to the reported event.
3.1.5. Miscellaneous/general
(25) The typical duration of surveillance for Failure to Thrive fol-
lowing antenatal vaccination is 12 months, however consid-
eration should be given to:
 Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines;
 Biologic characteristics of the vaccinee (e.g. nutrition,
underlying disease resulting in immunosuppression.
(26) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event.
(27) Methods of data collection should be consistent within and
between study groups, if applicable.
(28) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1 to 24.
(29) Investigators of patients with Failure to Thrive should pro-
vide guidance to reporters to optimise the quality and com-
pleteness of information provided.
(30) Reports of Failure to Thrive should be collected throughout
the study period regardless of the time elapsed between
immunisation and the adverse event. If this is not feasible
due to the study design, the study periods during which
safety data are being collected should be clearly defined.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on Failure to Thrive to allow for comparability of
data, and are recommended as an addition to data analysed for
the specific study question and setting.
(31) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
Event classification in 5 categories15
Event meets case definition
(1) Level 1: Criteria as specified in the Failure to Thrive case
definition
9 The date and/or time of onset is defined as the time post immunisation, when the
first sign or symptom indicative for Failure to Thrive occurred. This may only be
possible to determine in retrospect.
10 The date and/or time of first observation of the first sign or symptom indicative
for Failure to Thrive can be used if date/time of onset is not known.
11 The date of diagnosis of an episode is the day post immunisation when the event
met the case definition at any level.
12 The end of an episode is defined as the time the event no longer meets the case
definition at the lowest level of the definition.
13 E.g. recovery to pre-immunisation health status, spontaneous resolution, thera-
peutic intervention, persistence of the event, sequelae, death.
14 An AEFI is defined as serious by international standards if it meets one or more of
the following criteria: (1) it results in death, (2) is life-threatening, (3) it requires
inpatient hospitalisation or results in prolongation of existing hospitalisation, (4)
results in persistent or significant disability/incapacity, (5) is a congenital anomaly/
birth defect, (6) is a medically important event or reaction.
15 To determine the appropriate category, the user should first establish, whether a
reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of the
definition is met, and there is evidence that the criteria of the next higher level of
diagnostic certainty are met, the event should be classified in the next category. This
approach should be continued until the highest level of diagnostic certainty for a
given event could be determined. Major criteria can be used to satisfy the
requirement of minor criteria. If the lowest level of the case definition is not met, it
should be ruled out that any of the higher levels of diagnostic certainty are met and
the event should be classified in additional categories four or five.
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(2) Level 2: Criteria as specified in the Failure to Thrive case
definition
(3) Level 3: Criteria as specified in the Failure to Thrive case
definition
Event does not meet case definition
Additional categories for analysis
(4) Reported Failure to Thrive with insufficient evidence to meet
the case definition16
(5) Not a case of Failure to Thrive
(32) The interval between maternal immunisation and reported
Failure to Thrive could be defined as the date/time of mater-
nal immunisation to the date/time of onset8 of the first
symptoms and/or signs consistent with the definition. If
few cases are reported, the concrete time course could be
analysed for each; for a large number of cases, data can be
analysed in the following increments:
Subjects with Failure to Thrive by Interval to Presentation
Interval⁄ Number
<2 months after immunisation
2–<6 months after immunisation
6–<12 months after immunisation
12–<18 months after immunisation
Months increments thereafter
Total
(33) The duration of a possible Failure to Thrive could be anal-
ysed as the interval between the date/time of onset7 of the
first symptoms and/or signs consistent with the definition
and the end of episode11 and/or final outcome12. Whatever
start and ending are used, they should be used consistently
within and across study groups.
(34) If more than one measurement of a particular criterion is
taken and recorded, the value corresponding to the greatest
magnitude of the adverse experience could be used as the
basis for analysis. Analysis may also include other character-
istics like qualitative patterns of criteria defining the event.
(35) The distribution of data (as numerator and denominator
data) could be analysed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases is
presented, the respective values or time course can be pre-
sented individually.
(36) Data on Failure to Thrive obtained from subjects receiving a
vaccine should be compared with those obtained from an
appropriately selected and documented control group(s) to
assess background rates of hypersensitivity in non-exposed
populations, and should be analysed by study arm and dose
where possible, e.g. in prospective clinical trials.
3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on Failure to Thrive following mater-
nal immunisation to allow for comparability of data, and are
recommended as an addition to data presented for the specific
study question and setting. Additionally, it is recommended to
refer to existing general guidelines for the presentation and publi-
cation of randomised controlled trials, systematic reviews, and
meta-analyses of observational studies in epidemiology (e.g. state-
ments of Consolidated Standards of Reporting Trials (CONSORT), of
Improving the quality of reports of meta-analyses of randomised
controlled trials (QUORUM), and of Meta-analysis Of Observational
Studies in Epidemiology (MOOSE), respectively) [47].
(37) All reported events of Failure to Thrive should be presented
according to the categories listed in guideline 31.
(38) Data on possible Failure to Thrive events should be pre-
sented in accordance with data collection guidelines 1–24
and data analysis guidelines 31–36.
(39) Terms to describe Failure to Thrive such as ‘‘low-grade”,
‘‘mild”, ‘‘moderate”, ‘‘high”, ‘‘severe” or ‘‘significant” are
highly subjective, prone to wide interpretation, and should
be avoided, unless clearly defined.
(40) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunisation safety surveillance systems denomina-
tor data are usually not readily available, attempts should be made
to identify approximate denominators. The source of the denomi-
nator data should be reported and calculations of estimates be
described (e.g. manufacturer data like total doses distributed,
reporting through Ministry of Health, coverage/population based
data, etc.).
(41) The incidence of cases in the study population should be
presented and clearly identified as such in the text.
(42) If the distribution of data is skewed, median and range are
usually the more appropriate statistical descriptors than a
mean. However, the mean and standard deviation should
also be provided.
(43) Any publication of data on Failure to Thrive should include a
detailed description of the methods used for data collection
and analysis as possible. It is essential to specify:
 The study design;
 The method, frequency and duration of monitoring for
Failure to Thrive;
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation;
 The typeof surveillance (e.g. passive or active surveillance);
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation);
 The search strategy in surveillance databases;
 Comparison group(s), if used for analysis;
 The instrument of data collection (e.g. standardised ques-
tionnaire, diary card, report form);
 Whether the day of immunisation was considered ‘‘day
one” or ‘‘day zero” in the analysis;
 Whether the date of onset8 and/or the date of first obser-
vation9 and/or the date of diagnosis10 was used for anal-
ysis; and
 Use of this case definition for Failure to Thrive, in the
abstract or methods section of a publication17,18.
16 If the evidence available for an event is insufficient because information is
missing, such an event should be categorised as ‘‘Reported Failure to Thrive with
insufficient evidence to meet the case definition”.
17 An event does not meet the case definition if investigation reveals a negative
finding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classified as ‘‘Not a case of Failure to Thrive”.
18 Use of this document should preferably be referenced by referring to the
respective link on the Brighton Collaboration website (http://www.brightoncollabo-
ration.org).
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essarily represent the views of their respective institutions.
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